Risk assessment for benefits analysis: Framework for analysis of a thyroid-disrupting chemical

Journal of Toxicology and Environmental Health - Part A

Volumn 68, Issue 11-12, 2005, Pages 837-855

  Axelrad, Daniel A ^a   Baetcke, Karl ^a   Dockins, Chris ^a   Griffiths, Charles W ^a   Hill, Richard N ^a   Murphy, Patricia A ^a   Owens, Nicole ^a   Simon, Nathalie B ^a   Teuschler, Linda K ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; ANTITHYROID AGENT;

ANALYTIC METHOD; ASSAY; CARCINOGENIC ACTIVITY; CASE STUDY; CHEMICAL ENVIRONMENT; CHEMICAL MUTAGENESIS; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; HUMAN; HYPOPHYSIS FUNCTION; HYPOTHYROIDISM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION; THYROID TUMOR; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; ECONOMICS; METHODOLOGY;

ANIMALIA;

ANIMALS; ANTITHYROID AGENTS; CARCINOGENS, ENVIRONMENTAL; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOTHYROIDISM; RISK ASSESSMENT;

EID: 23644448439     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390590912153     Document Type: Conference Paper

References (34)

1. Anderson, R. N. 1999. United States life tables, 1997. Natl. Vital Stat. Rep. 47(28).
2. Canaris, G. J., Manowitz, N. R., Mayor, G., and Ridgway, E. C. 2000. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160:526-534.
3. Crump, K. S. 1984. A new method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4:854-871.
4. Crump, K. S. 1995. Calculation of benchmark doses from continuous data. Risk Anal. 15:79-89.
5. Danese, M. D., Powe, N. R., Sawin, C. T., and Ladenson, P. W. 1996. Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis. J. Am. Med. Assoc. 276:285-292.
6. Döhler, K. D., Wong, C. C., and von zur Mühlen, A. 1979. The rat as a model for the study of drug effects on thyroid function: Consideration of methodological problems. Pharmacol. Ther. 5:305-318.
7. Dourson, M. L., Teuschler, L. K., Durkin, P. R., and Stiteler, W. M. 1997. Categorical regression of toxicity data: A case study using aldicarb. Regul. Toxicol. Pharmacol. 25:121-129.
8. Farland, W., and Dourson, M. L. 1992. Noncancer health endpoints: approaches to quantitative risk assessment. In Comparative environmental risk assessment, R. Cothern, pp. 87-106. Boca Raton, LA: Lewis.
9. Freeman, A. M. III. 2003. The measurement of environmental and resource values: Theory and methods, 2nd ed. Washington, DC.: Resources for the Future.
10. Gaylor, D., and Slikker, W., Jr. 1990. Risk assessment for neurotoxic effects. Neurotoxicology 11:211-218.
11. Haddow, J. E., Palomaki, G. E., Allan, W. C., Williams, J. R., Knight, G. J., Gagnon, J., O'Heir, C. E., Mitchell, M. L., Hermos, R. J. Waisbren, S. E., Faix, J. D., and Klein, R. Z. 1999. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N. Engl. J. Med. 341:549-555.
12. Hertzberg, R. C. 1989. Extrapolation and scaling of animal data to humans: Fitting a model to categorical response data with application to species extrapolation of toxicity. Health Phys. 57(suppl. 1):405-409.
13. Hertzberg, R. C., and Miller, M. 1985. A statistical model for species extrapolating using categorical response data. Toxicol. Ind. Health 1:43-63.
14. Hundahl, S. A., Fleming, I. D., Fremgen, A. M., and Menck, H. R. 1998. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
15. International Agency for Research on Cancer. 1999. Species differences in thyroid, kidney and urinary bladder carcinogenesis. Lyon, France: IARC. Scientific Publication No. 147.
16. Kodell, R. L., Chen, J. J., and Gaylor, D. W. 1995. Neurotoxicity modeling for risk assessment. Regul Toxicol. Pharmacol. 22:24-29.
17. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33:591-653.
18. Morreale de Escobar, G., Obregón, M. J., and Escobar del Rey, F. 2000. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? J. Clin. Endocrinol. Metab. 85:3975-3987.
19. Pop, V. J., Brouwers, E. P., Vader, H. L., Vulsma, T., van Baar, A. L., and de Vijlder, J. J. 2003. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: A 3-year follow-up study. Clin. Endocrinol. (Oxf.) 59:282-288.
20. Rao, V. R., Levy, K., and Lustik, M. 1993. Logistic regression of inhalation toxicities of perchloroethylene: Application in noncancer risk assessment. Regul. Toxicol. Pharmacol. 18:233-247.
21. Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L., and Edwards, B. K., eds. 2000. SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute.
22. Teuschler, L. K., Dourson, M. L., Stiteler, W. M., McClure, P., and Tully, H. 1999. Health risk above the reference dose for multiple chemicals. Regul. Toxicol. Pharmacol. 30(2 Pt. 2):S19-26.
23. U.S. Environmental Protection Agency. 1986. Guidelines for carcinogen risk assessment. Fed. Reg. 51:33992.
24. U.S. Environmental Protection Agency. 1994. Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. Washington, DC: Office of Research and Development, Office of Health and Environmental Assessment. EPA/600/8-90/066F.
25. U.S. Environmental Protection Agency. 1997. The benefits and costs of the Clean Air Act, 1970-1990. Washington, DC: U.S. EPA. EPA/410/R-97/002.
26. U.S. Environmental Protection Agency. 1998. Assessment of thyroid follicular cell tumors. Washington, DC: Risk Assessment Forum. http://www.epa.gov/ncea/thyroid.htm.
27. U.S. Environmental Protection Agency. 1999. Guidelines for carcinogen risk assessment. Review draft. Washington, DC: Risk Assessment Forum. http://www.epa.gov/ncea/raf/cancer.htm.
28. U.S. Environmental Protection Agency. 2000a. Benchmark dose technical guidance document. External review draft. Washington, DC: Risk Assessment Forum. EPA/630/R-00/001. http://www.epa.gov/ncea/bnchmrk/bmds_peer.htm.
29. U.S. Environmental Protection Agency. 2000b. Guidelines for preparing economic analyses. Washington, DC: Office of the Administrator. EPA/240/R-00/03. http://yosemite.epa.gov/ee/epa/eed.nsf/webpages/Guidelines.html.
30. U.S. Environmental Protection Agency. 2000c. CATREG software user manual. Washington, DC: Office of Research and Development. EPA/600/R-98/052F.
31. U.S. Environmental Protection Agency. 2000d. CATREG software documentation. Washington, DC: Office of Research and Development. EPA/600/R-98/053F.
32. U.S. Environmental Protection Agency. 2002. A review of the reference dose and reference concentration processes. Washington, DC: Risk Assessment Forum. EPA/630/P-02/002F. http://epa.gov/ncea/raf/ratpub.htm.
33. U.S. Environmental Protection Agency. 2005. Guidelines for Carcinogen Risk Assessment Washington. http://cfpub.epa.gov/ncea/raf/recordisplay.cfm? deild=116283.
34. U.S. Office of Management and Budget. 2001. Making sense of regulation: 2001 Report to Congress on the costs and benefits of regulations and unfunded mandates on state, local and tribal entities. Washington, DC: OMB, Office of Information and Regulatory Affairs. http://www.whitehouse.gov/omb/inforeg/ costbenefitreport.pdf.